Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
54
TBI Quote, Financials, Valuation and Earnings
Last price:
$6.90
Seasonality move
:
-0.43%
Day range:
$6.20 - $6.55
52-week range:
$3.45 - $12.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.13x
P/B ratio:
0.64x
Volume:
177.9K
Avg. volume:
204.1K
1-year change:
-41.46%
Market cap:
$193.5M
Revenue:
$1.6B
EPS (TTM):
-$4.59
Analysts' Opinion
-
Consensus RatingTrueBlue has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.33, TrueBlue has an estimated upside of 28.6% from its current price of $6.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $6.48.
Fair Value
-
According to the consensus of 3 analysts, TrueBlue has 28.6% upside to fair value with a price target of $8.33 per share.
TBI vs. S&P 500
-
Over the past 5 trading days, TrueBlue has underperformed the S&P 500 by -2.32% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
TrueBlue does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TrueBlue revenues have been falling on a year-over-year basis for 11 quarters in a row. In the most recent quarter TrueBlue reported revenues of $370.3M.
Earnings Growth
-
TrueBlue earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter TrueBlue reported earnings per share of -$0.48.
Enterprise value:
228.3M
EV / Invested capital:
--
Price / LTM sales:
0.13x
EV / EBIT:
--
EV / Revenue:
0.15x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-4.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
129.41x
Gross Profit (TTM):
$393.3M
Return On Assets:
-18.89%
Net Income Margin (TTM):
-9.02%
Return On Equity:
-40.03%
Return On Invested Capital:
-38.57%
Operating Margin:
-3.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.2B | $1.8B | $1.5B | $402.9M | $370.3M | |
| Gross Profit | $585.4M | $482.3M | $393.3M | $99.4M | $86.3M | |
| Operating Income | $54.3M | -$23.9M | -$31.7M | -$15.5M | -$14.1M | |
| EBITDA | $82.6M | $3.4M | -$3.3M | -$7.6M | -$7.3M | |
| Diluted EPS | $1.43 | -$0.37 | -$4.59 | -$0.05 | -$0.48 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $384M | $398.3M | $371.3M | $315.4M | $281M | |
| Total Assets | $979.4M | $980.9M | $957.1M | $868.6M | $692.5M | |
| Current Liabilities | $258.5M | $225.9M | $214.9M | $184M | $156.3M | |
| Total Liabilities | $533.8M | $513.4M | $489.5M | $422.2M | $390.3M | |
| Total Equity | $445.6M | $467.6M | $467.6M | $446.4M | $302.2M | |
| Total Debt | -- | $4M | -- | -- | $57.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $103.2M | $11.4M | -$24.9M | -$14.2M | -$22.1M | |
| Cash From Investing | -$29.6M | -$23M | -$27.3M | $919K | -$24M | |
| Cash From Financing | -$55.5M | -$24.4M | $45.9M | -$13.7M | $49.4M | |
| Free Cash Flow | $70.3M | -$19.2M | -$46.4M | -$21.6M | -$26.8M | |
TBI
Sector
Market Cap
$193.5M
$611.3M
Price % of 52-Week High
52.73%
81.21%
Dividend Yield
0%
0%
Shareholder Yield
0.55%
2.28%
1-Year Price Total Return
-41.46%
-1.12%
Beta (5-Year)
1.531
0.761
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.43
200-day SMA
Sell
Level
$6.68
Bollinger Bands (100)
Buy
Level
4.76 - 6.5
Chaikin Money Flow
Sell
Level
-64.3K
20-day SMA
Sell
Level
$6.58
Relative Strength Index (RSI14)
Buy
Level
52.62
ADX Line
Sell
Level
27.78
Williams %R
Neutral
Level
-46.8208
50-day SMA
Buy
Level
$6.01
MACD (12, 26)
Buy
Level
1.66
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-211.2K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4808)
Buy
CA Score
(Annual)
Level (0.0868)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.0344)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
Stock Forecast FAQ
In the current month, TBI has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The TBI average analyst price target in the past 3 months is $8.33.
-
Where Will TrueBlue Stock Be In 1 Year?
According to analysts, the consensus estimate is that TrueBlue share price will rise to $8.33 per share over the next 12 months.
-
What Do Analysts Say About TrueBlue?
Analysts are divided on their view about TrueBlue share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TrueBlue is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is TrueBlue's Price Target?
The price target for TrueBlue over the next 1-year time period is forecast to be $8.33 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is TBI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TrueBlue is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TBI?
You can purchase shares of TrueBlue via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TrueBlue shares.
-
What Is The TrueBlue Share Price Today?
TrueBlue was last trading at $6.90 per share. This represents the most recent stock quote for TrueBlue. Yesterday, TrueBlue closed at $6.48 per share.
-
How To Buy TrueBlue Stock Online?
In order to purchase TrueBlue stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
